{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=23", "query": { "condition": "Relapsed/Refractory", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 3666, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T02:02:37.669Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06678659", "title": "A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable", "Locally Advanced", "Metastatic Cancers", "Relapsed/Refractory Lymphomas" ], "interventions": [ { "name": "REC-1245", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Recursion Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 170, "start_date": "2024-11-21", "completion_date": "2028-10-30", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-14T02:02:37.669Z", "location_count": 5, "location_summary": "Duarte, California • Santa Monica, California • Cleveland, Ohio + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06678659" }, { "nct_id": "NCT00003885", "title": "Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Our Lady of Mercy Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "1997-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-06", "last_synced_at": "2026-11-14T02:02:37.669Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003885" }, { "nct_id": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Acute Leukemia of Ambiguous Lineage", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "Chemosensitivity Assay", "type": "OTHER" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Gene Expression Analysis", "type": "GENETIC" }, { "name": "Genetic Variation Analysis", "type": "GENETIC" }, { "name": "In Vitro Sensitivity-Directed Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "OTHER", "GENETIC", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-11", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-11-14T02:02:37.669Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02551718" }, { "nct_id": "NCT05662397", "title": "A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Relapsed Cancer", "Refractory Cancer" ], "interventions": [ { "name": "HST-1011", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "HotSpot Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2023-03-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-11-14T02:02:37.669Z", "location_count": 8, "location_summary": "Sarasota, Florida • Las Vegas, Nevada • New York, New York + 5 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05662397" }, { "nct_id": "NCT03867682", "title": "Venetoclax and Lintuzumab-Ac225 in AML Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Relapsed Adult AML" ], "interventions": [ { "name": "Lintuzumab-Ac225", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Spironolactone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Actinium Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2020-01-15", "completion_date": "2024-06", "has_results": false, "last_update_posted_date": "2023-08-04", "last_synced_at": "2026-11-14T02:02:37.669Z", "location_count": 5, "location_summary": "Los Angeles, California • Louisville, Kentucky • New Orleans, Louisiana + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03867682" }, { "nct_id": "NCT03786926", "title": "Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "HMPL-689", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2019-08-26", "completion_date": "2024-06-26", "has_results": true, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-11-14T02:02:37.669Z", "location_count": 10, "location_summary": "Anaheim, California • Oxnard, California • Atlanta, Georgia + 6 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Westbury", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03786926" }, { "nct_id": "NCT06119685", "title": "IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NHL", "Multiple Myeloma", "Blood Cancer", "Refractory Non-Hodgkin Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Refractory Multiple Myeloma", "Relapsed Multiple Myeloma" ], "interventions": [ { "name": "IDP-023", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indapta Therapeutics, INC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2023-10-25", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-11-14T02:02:37.669Z", "location_count": 12, "location_summary": "Los Angeles, California • Lake Mary, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06119685" }, { "nct_id": "NCT03441048", "title": "Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Lintuzumab-Ac-225", "type": "BIOLOGICAL" }, { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2018-05-22", "completion_date": "2024-05-22", "has_results": false, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-11-14T02:02:37.669Z", "location_count": 1, "location_summary": "Milwuakee, Wisconsin", "locations": [ { "city": "Milwuakee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03441048" }, { "nct_id": "NCT03650491", "title": "A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Multiple Myeloma in Relapse", "Multiple Myeloma With Failed Remission" ], "interventions": [ { "name": "FOR46", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fortis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2019-04-03", "completion_date": "2022-01-31", "has_results": false, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-11-14T02:02:37.669Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03650491" }, { "nct_id": "NCT00796055", "title": "Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "MEDI-547", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2009-08", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2011-11-17", "last_synced_at": "2026-11-14T02:02:37.669Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Detroit, Michigan", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00796055" } ] }